Literature DB >> 34648131

Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most.

Morgan M Philbin1,2, Sadie Bergen3, Carrigan Parish3, Deanna Kerrigan4, Elizabeth N Kinnard5, Sarah Reed3, Mardge H Cohen6, Oluwakemi Sosanya7, Anandi N Sheth8, Adaora A Adimora9,10, Jennifer Cocohoba11, Lakshmi Goparaju12, Elizabeth T Golub13, Michael Vaughn14, José I Gutierrez15, Margaret A Fischl16, Maria Alcaide16, Lisa R Metsch3.   

Abstract

Long-acting injectable (LAI) modalities have been developed for ART and PrEP. Women face unique barriers to LAI use yet little research has examined women's perceptions of potential LAI HIV therapy candidates. We conducted 89 in-depth interviews at six Women's Interagency HIV Study (WIHS) sites with women living with HIV (n = 59) and HIV-negative women (n = 30) from 2017 to 2018. Interviews were recorded, transcribed, and analyzed using thematic content analysis. Participants identified specific sub-populations who could most benefit from LAI over daily pills: (1) young people; (2) women with childcare responsibilities; (3) people with adherence-related psychological distress; (4) individuals with multiple sex partners; and (5) people facing structural insecurities such as homelessness. Women are underserved by current HIV care options and their perspectives are imperative to ensure a successful scale-up of LAI PrEP and LAI ART that prioritizes equitable access and benefit for all individuals.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antiretroviral therapy (ART); HIV/AIDS; Long-acting injectable (LAI); Pre-exposure prophylaxis (PrEP); Qualitative research; Women

Mesh:

Substances:

Year:  2021        PMID: 34648131      PMCID: PMC8940643          DOI: 10.1007/s10461-021-03483-7

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  60 in total

1.  HIV disclosure and other factors that impact on adherence to antiretroviral therapy: the case of Soweto, South Africa.

Authors:  Nokuthula L Skhosana; Helen Struthers; Glenda E Gray; James A McIntyre
Journal:  Afr J AIDS Res       Date:  2006-05       Impact factor: 1.300

Review 2.  A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy.

Authors:  Kasey R Claborn; Ellen Meier; Mary Beth Miller; Thad R Leffingwell
Journal:  Psychol Health Med       Date:  2014-08-11       Impact factor: 2.423

Review 3.  Constructions of masculinity and their influence on men's well-being: a theory of gender and health.

Authors:  W H Courtenay
Journal:  Soc Sci Med       Date:  2000-05       Impact factor: 4.634

4.  Interest of Youth Living With HIV in Long-Acting Antiretrovirals.

Authors:  Ethel D Weld; Md Sohel Rana; Ronald H Dallas; Andres F Camacho-Gonzalez; Patrick Ryscavage; Aditya H Gaur; Rana Chakraborty; Susan Swindells; Charles Flexner; Allison L Agwu
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

5.  Perceived barriers to pre-exposure prophylaxis use and the role of syndemic factors among female sex workers in the Mexico-United States border region: a latent class analysis.

Authors:  Jennifer P Jain; Steffanie A Strathdee; Thomas L Patterson; Shirley J Semple; Alicia Harvey-Vera; Carlos Magis-Rodríguez; Gustavo Martinez; Heather A Pines
Journal:  AIDS Care       Date:  2019-06-04

6.  Adaptation of an HIV Medication Adherence Intervention for Adolescents and Young Adults.

Authors:  Idia B Thurston; Laura M Bogart; Madeline Wachman; Elizabeth F Closson; Margie R Skeer; Matthew J Mimiaga
Journal:  Cogn Behav Pract       Date:  2014-05

7.  Preferences for Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men Who Have Sex with Men.

Authors:  Katie B Biello; Sybil Hosek; Morgan T Drucker; Marvin Belzer; Matthew J Mimiaga; Elliot Marrow; Julia Coffey-Esquivel; Jennifer Brothers; Kenneth H Mayer
Journal:  Arch Sex Behav       Date:  2017-09-19

8.  High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.

Authors:  Kathrine Meyers; Kristina Rodriguez; Robert W Moeller; Ilana Gratch; Martin Markowitz; Perry N Halkitis
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

Review 9.  Mental health and HIV/AIDS: the need for an integrated response.

Authors:  Robert H Remien; Michael J Stirratt; Nadia Nguyen; Reuben N Robbins; Andrea N Pala; Claude A Mellins
Journal:  AIDS       Date:  2019-07-15       Impact factor: 4.177

10.  Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).

Authors:  Elizabeth E Tolley; Sue Li; Sahar Z Zangeneh; Millicent Atujuna; Petina Musara; Jessica Justman; Subash Pathak; Linda-Gail Bekker; Shobha Swaminathan; Jill Stanton; Jennifer Farrior; Nirupama Sista
Journal:  J Int AIDS Soc       Date:  2019-10       Impact factor: 5.396

View more
  3 in total

1.  Long-Acting Injectable Human Immunodeficiency Virus Pre-Exposure Prophylaxis Preferred Over Other Modalities Among People Who Inject Drugs: Findings from a Qualitative Study in California.

Authors:  Angela R Bazzi; Chad J Valasek; Samantha A Streuli; Carlos F Vera; Alicia Harvey-Vera; Morgan M Philbin; Katie B Biello; Alexis M Roth; Steffanie A Strathdee; Heather A Pines
Journal:  AIDS Patient Care STDS       Date:  2022-06-21       Impact factor: 5.944

Review 2.  Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV.

Authors:  Morgan M Philbin; Amaya Perez-Brumer
Journal:  Curr Opin HIV AIDS       Date:  2022-03-01       Impact factor: 4.283

3.  Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South.

Authors:  Lauren F Collins; Della Corbin-Johnson; Meron Asrat; Zoey P Morton; Kaylin Dance; Alton Condra; Kimberly Jenkins; Marie Todd-Turner; Jeri Sumitani; Bradley L Smith; Wendy S Armstrong; Jonathan A Colasanti
Journal:  Open Forum Infect Dis       Date:  2022-09-02       Impact factor: 4.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.